Results 21 to 30 of about 701,417 (304)

How to maintain the maximal level of blinding in randomisation for a placebo-controlled drug trial

open access: yesContemporary Clinical Trials Communications, 2019
We illustrate the approach of randomising treatments and compare it with the traditional approach of randomising patients, using a case study drawn from the authors’ experience in clinical trials. The setting is a double-blind parallel two-arm randomised
Lei Clifton, David A. Clifton
doaj   +1 more source

Oral herbal therapies for treating osteoarthritis (review) [PDF]

open access: yes, 2014
Background Medicinal plant products are used orally for treating osteoarthritis. Although their mechanisms of action have not yet been elucidated in full detail, interactions with common inflammatory mediators provide a rationale for using them to ...
Cameron, Melainie, Chrubasik, Sigrun
core   +1 more source

Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison [PDF]

open access: yes, 2018
Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor ...
Gandhi, Kunal   +8 more
core   +2 more sources

Caffeine supplementation improves countermovement jump in youth soccer players: a pilot study

open access: yesRevista Española de Nutrición Humana y Dietética, 2017
Introduction: The objective of this study was to analyze the effect of caffeine ingestion in soccer performance, particularly in the countermovement jump test (CMJ).
Juan Diego Hernández-Camacho   +3 more
doaj   +1 more source

Steroids in pediatric eosinophilic esophagitis [PDF]

open access: yes, 2014
Swallowed fluticasone and oral viscous budesonide are effective first-line therapies for eosinophilic esophagitis in children. Side effects are minimal without evidence of Cushing syndrome, as seen in treatment with systemic corticosteroids.
Contreras, Emily M., Gupta, Sandeep K.
core   +1 more source

Purified and specific cytoplasmic pollen extract: a non-hormonal alternative for the treatment of menopausal symptoms. [PDF]

open access: yes, 2020
Research into non-hormonal, alternative therapies is necessary for women for whom menopausal hormone therapy is contraindicated or for women who do not wish to take hormones.
Biglia, Nicoletta   +14 more
core   +4 more sources

Participant Blinding and Gastrointestinal Illness in a Randomized, Controlled Trial of an In-Home Drinking Water Intervention

open access: yesEmerging Infectious Diseases, 2002
We conducted a randomized, triple-blinded home drinking water intervention trial to determine if a large study could be undertaken while successfully blinding participants.
John M. Colford   +13 more
doaj   +1 more source

Tennis elbow, study protocol for a randomized clinical trial: needling with and without platelet-rich plasma after failure of up-to-date rehabilitation

open access: yesJournal of Orthopaedic Surgery and Research, 2020
Background The conservative management of lateral epicondylitis is known to be a difficult-to-treat annoying condition. A treatment with platelet-rich plasma (PRP) is often performed, but its efficacy remains controversial. Methods This study is a single-
A. J. Schwitzguebel   +4 more
doaj   +1 more source

Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis [PDF]

open access: yes, 2015
Peer reviewedPublisher ...
Azuara-Blanco, Augusto   +4 more
core   +1 more source

Interferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a Dose-C omparison Study [PDF]

open access: yes, 2004
Background: Multiple sclerosis (MS) is a chronic disease requiring long-term monitoring of treatment. Objective: To assess the four-year clinical efficacy of intramuscular (IM) IFNb-1a in patients with relapsing MS from the European IFNb-1a Dose-C ...
Achiti, J.   +98 more
core   +1 more source

Home - About - Disclaimer - Privacy